Glenmark Pharmaceuticals (GLENMARK) Stock Overview
Develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
GLENMARK Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Glenmark Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,997.60 |
| 52 Week High | ₹2,284.80 |
| 52 Week Low | ₹1,275.50 |
| Beta | 0.29 |
| 1 Month Change | -0.15% |
| 3 Month Change | 6.89% |
| 1 Year Change | 50.98% |
| 3 Year Change | 358.22% |
| 5 Year Change | 314.23% |
| Change since IPO | 7,266.48% |
Recent News & Updates
Recent updates
Glenmark Pharmaceuticals Limited Just Beat Revenue By 16%: Here's What Analysts Think Will Happen Next
Nov 19
Getting In Cheap On Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Might Be Difficult
Nov 12Here's Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Is The Least Of Shareholders' Concerns
Sep 20Glenmark Pharmaceuticals (NSE:GLENMARK) Seems To Use Debt Quite Sensibly
Jul 14Investor Optimism Abounds Glenmark Pharmaceuticals Limited (NSE:GLENMARK) But Growth Is Lacking
Jun 23Glenmark Pharmaceuticals' (NSE:GLENMARK) Earnings Are Weaker Than They Seem
Jun 02
Lirafit Launch And BeiGene Partnership Set To Accelerate Revenue Growth And Market Share
Upcoming biosimilar launches and strategic oncology partnerships could significantly boost Glenmark's revenue and market share in India.Shareholder Returns
| GLENMARK | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.2% | 0.6% | -0.4% |
| 1Y | 51.0% | 4.4% | 11.0% |
Return vs Industry: GLENMARK exceeded the Indian Pharmaceuticals industry which returned 4.4% over the past year.
Return vs Market: GLENMARK exceeded the Indian Market which returned 11% over the past year.
Price Volatility
| GLENMARK volatility | |
|---|---|
| GLENMARK Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Stable Share Price: GLENMARK has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: GLENMARK's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1977 | 15,800 | Glenn Saldanha | glenmarkpharma.com |
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors.
Glenmark Pharmaceuticals Limited Fundamentals Summary
| GLENMARK fundamental statistics | |
|---|---|
| Market cap | ₹563.72b |
| Earnings (TTM) | ₹10.65b |
| Revenue (TTM) | ₹165.10b |
Is GLENMARK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLENMARK income statement (TTM) | |
|---|---|
| Revenue | ₹165.10b |
| Cost of Revenue | ₹48.36b |
| Gross Profit | ₹116.74b |
| Other Expenses | ₹106.09b |
| Earnings | ₹10.65b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 37.74 |
| Gross Margin | 70.71% |
| Net Profit Margin | 6.45% |
| Debt/Equity Ratio | 12.8% |
How did GLENMARK perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/15 05:49 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Glenmark Pharmaceuticals Limited is covered by 42 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Ganeshram Jayaraman | Avendus Spark |